|
|
Office Locations:
|
424 West 33rd St., Suite 330
New York, NY 10001
Phone: 646-227-5270
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
Merlin Nexus is a company focused on crossover private equity investing in the life sciences industry. Merlin Nexus invests globally in private and public healthcare companies. With its first fund launched in 2001 by Dominique Semon, Merlin Nexus now has several crossover private equity funds and a public-only fund, with commitments totaling $200 million. The Merlin Nexus objective is to realize long-term capital appreciation from investments in: Late-stage private companies; PIPEs (Private Investments in Public Equity); and select, long-term, open market investments. Unlike venture capital funds, Merlin Nexus funds are distinguished by relatively high liquidity and by short, 5-year maturities. The firm targets for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
